1.Guidelines for Manufacturing and Application of Organoids: Brain
Taehwan KWAK ; Si-Hyung PARK ; Siyoung LEE ; Yujeong SHIN ; Ki-Jun YOON ; Seung-Woo CHO ; Jong-Chan PARK ; Seung-Ho YANG ; Heeyeong CHO ; Heh-In IM ; Sun-Ju AHN ; Woong SUN ; Ji Hun YANG
International Journal of Stem Cells 2024;17(2):158-181
This study offers a comprehensive overview of brain organoids for researchers. It combines expert opinions with technical summaries on organoid definitions, characteristics, culture methods, and quality control. This approach aims to enhance the utilization of brain organoids in research. Brain organoids, as three-dimensional human cell models mimicking the nervous system, hold immense promise for studying the human brain. They offer advantages over traditional methods, replicating anatomical structures, physiological features, and complex neuronal networks. Additionally, brain organoids can model nervous system development and interactions between cell types and the microenvironment. By providing a foundation for utilizing the most human-relevant tissue models, this work empowers researchers to overcome limitations of two-dimensional cultures and conduct advanced disease modeling research.
2.A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway.
Sae-Bom YOON ; Hyowon HONG ; Hee-Jong LIM ; Ji Hye CHOI ; Yoon Pyo CHOI ; Seong Wook SEO ; Hyuk Woo LEE ; Chong Hak CHAE ; Woo-Kyu PARK ; Hyun Young KIM ; Daeyoung JEONG ; Tran Quang DE ; Chang-Seon MYUNG ; Heeyeong CHO
Acta Pharmaceutica Sinica B 2023;13(3):1093-1109
Interleukin-1 receptor-associated kinase 4 (IRAK4) is a pivotal enzyme in the Toll-like receptor (TLR)/MYD88 dependent signaling pathway, which is highly activated in rheumatoid arthritis tissues and activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL). Inflammatory responses followed by IRAK4 activation promote B-cell proliferation and aggressiveness of lymphoma. Moreover, proviral integration site for Moloney murine leukemia virus 1 (PIM1) functions as an anti-apoptotic kinase in propagation of ABC-DLBCL with ibrutinib resistance. We developed a dual IRAK4/PIM1 inhibitor KIC-0101 that potently suppresses the NF-κB pathway and proinflammatory cytokine induction in vitro and in vivo. In rheumatoid arthritis mouse models, treatment with KIC-0101 significantly ameliorated cartilage damage and inflammation. KIC-0101 inhibited the nuclear translocation of NF-κB and activation of JAK/STAT pathway in ABC-DLBCLs. In addition, KIC-0101 exhibited an anti-tumor effect on ibrutinib-resistant cells by synergistic dual suppression of TLR/MYD88-mediated NF-κB pathway and PIM1 kinase. Our results suggest that KIC-0101 is a promising drug candidate for autoimmune diseases and ibrutinib-resistant B-cell lymphomas.